Fed. Circ. Won't Let Jazz Keep System Patent In Orange Book

By Dani Kass · February 24, 2023, 7:43 PM EST

Jazz Pharmaceuticals must remove a patent from the Orange Book listing for its blockbuster narcolepsy drug Xyrem, as it covers neither the drug itself nor a method of using it, the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

November 28, 2022

Recent Articles By Dani

November 06, 2024
How The Patent System May Look After Trump's Return
October 17, 2024
Justices Urged To Fix 'Novel Misreading' Of IP Safe Harbor
October 07, 2024
Fed. Circ. Questions If Safer OxyContin Profits Came From IP
September 27, 2024
Kappos' Bayh-Dole Warning To Clients Draws Debate
September 24, 2024
Novo Nordisk Tells Sens. Ozempic Costs Are Linked To PBMs
August 13, 2024
Entresto Release Delayed As Novartis Goes To Fed. Circ.
August 06, 2024
Fed. Circ. Told Edwards Filed Safe Harbor Suit With Bad Intent
July 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer Feedback
May 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor
April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor